We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study.
- Authors
Ashizawa, Tetsuo; Figueroa, Karla P.; Perlman, Susan L.; Gomez, Christopher M.; Wilmot, George R.; Schmahmann, Jeremy D.; Ying, Sarah H.; Zesiewicz, Theresa A.; Paulson, Henry L.; Shakkottai, Vikram G.; Bushara, Khalaf O.; Kuo, Sheng-Han; Geschwind, Michael D.; Xia, Guangbin; Mazzoni, Pietro; Krischer, Jeffrey P.; Cuthbertson, David; Holbert, Amy Roberts; Ferguson, John H.; Pulst, Stefan M.
- Abstract
Background All spinocerebellar ataxias (SCAs) are rare diseases. SCA1, 2, 3 and 6 are the four most common SCAs, all caused by expanded polyglutamine-coding CAG repeats. Their pathomechanisms are becoming increasingly clear and well-designed clinical trials will be needed. Methods To characterize the clinical manifestations of spinocerebellar ataxia (SCA) 1, 2, 3 and 6 and their natural histories in the United States (US), we conducted a prospective multicenter study utilized a protocol identical to the European consortium study, using the Scale for the Assessment and Rating of Ataxia (SARA) score as the primary outcome, with follow-ups every 6 months up to 2 years. Results We enrolled 345 patients (60 SCA1, 75 SCA2, 138 SCA3 and 72 SCA6) at 12 US centers. SCA6 patients had a significantly later onset, and SCA2 patients showed greater upper-body ataxia than patients with the remaining SCAs. The annual increase of SARA score was greater in SCA1 patients (mean ± SE: 1.61 ± 0.41) than in SCA2 (0.71 ± 0.31), SCA3 (0.65 ± 0.24) and SCA6 (0.87 ± 0.28) patients (p = 0.049). The functional stage also worsened faster in SCA1 than in SCA2, 3 and 6 (p = 0.002). Conclusions The proportions of different SCA patients in US differ from those in the European consortium study, but as in the European patients, SCA1 progress faster than those with SCA2, 3 and 6. Later onset in SCA6 and greater upper body ataxia in SCA2 were noted. We conclude that progression rates of these SCAs were comparable between US and Europe cohorts, suggesting the feasibility of international collaborative clinical studies.
- Subjects
SPINOCEREBELLAR ataxia; POLYGLUTAMINE; CLINICAL trials; HEALTH outcome assessment; ATAXIA
- Publication
Orphanet Journal of Rare Diseases, 2013, Vol 8, Issue 1, p1
- ISSN
1750-1172
- Publication type
Article
- DOI
10.1186/1750-1172-8-177